MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2024 International Congress

    Non-interventional phase 0 study for the collection of biospecimens from patients with Parkinson’s Disease (PD) to support the development of a diagnostic classifier for LRRK2-driven PD

    L. Desnoyers, S. Dheerendra, C. Wong, T. Dang, S. Esmaeeli, M. van Derbrug, M. Nalls, A. Ellenbogen, S. Jackson (South San Francisco, USA)

    Objective: Measure LRRK2 pathway activity in Parkinson’s Disease patients stratified using a genetic predictive classifier model. Background: Extensive research has shown that overactivation of the…
  • 2024 International Congress

    Overview of Phase 3 Trials of Continuous Subcutaneous Apomorphine Infusion for PD Patients with Motor Fluctuations

    R. Pahwa, T. van Laar, K. Dashtipour, G. Ceresoli-Borroni (Kansas City, USA)

    Objective: Review available efficacy data from Phase 3 studies assessing continuous subcutaneous apomorphine infusion (CSAI) for patients with PD experiencing motor fluctuations. Background: Despite decades…
  • 2024 International Congress

    Neuroprotective Action of Betulin in Parkinson’s disease: Alleviating Mitochondrial Dysfunction and Oxidative Stress-Induced Apoptosis in rat model

    A. Kumar (Allahabad, India)

    Objective: The objective of this study was to evaluate the neuroprotective efficacy of Betulin in MPTP-induced mice models of Parkinson's disease (PD), focusing on its…
  • 2024 International Congress

    Autoradiography characterization of novel alpha-synuclein radioligands [3H]Tg1-90B, [3H]M503-1619 and [3H]HY-2-15 in human post mortem brain

    D. Saturnino Guarino, G. Tian, K. Ho Young, H. Cj, V. Lee, K. Luk, R. Mach (Philadelphia, USA)

    Objective: To characterize the in vitro binding properties of 3 radioligands for imaging α-syn aggregates in post mortem brain samples of synucleinopathies: [3H]TG-190B (Site 2),…
  • 2024 International Congress

    Attitudes and Beliefs Towards Medication Burden and Deprescribing in Parkinson Disease

    TP. Pham Nguyen, D. Thibault, A. Hamedani, A. Willis (Philadelphia, USA)

    Objective: To examine the attitudes and beliefs about medication burden and deprescribing among persons living with Parkinson disease (PD) Background: Deprescribing of potentially inappropriate medications…
  • 2024 International Congress

    Clinical benefit of Opicapone in patients with different Parkinson disease phenopytes. The OPTIMO study

    MR. Luquin, C. Martin, I. Tegel, I. Pijuan, C. Moreno (Pamplona, Spain)

    Objective: To assess the clinical benefit induced by opicapone (OPC) as an add-on therapy to levodopa in fluctuating Parkinson’s disease (PD) patients with special focus…
  • 2024 International Congress

    Bioreactor-produced iPSCs-derived Dopaminergic Neuron-containing Neural Microtissues Innervate and Restore Motor Function in a Dose-dependent Manner in a Parkinson Rat Model

    N. Prudon, L. Cordero-Espinoza, M. Abarkan, B. Gurchenkov, C. Morel, M. Lepleux, V. de Luca, N. Pujol, L. Milvoy, P. Morand, F. Moncaubeig, H. Wurtz, L. Poinçot, M. Demarco, A. Jonckeau, J. Plétenka, E. Luquet, K. Schmit, L. Piouceau, S. Guilbert, L. Manache-Alberici, M. Lanero, G. Dabee, T. Dufourd, J. Schroeder, K. Alessandri, E. Bezard, E. Faggiani, M. Feyeux (Bordeaux, France)

    Objective: To demonstrate the efficacy of a ready-to-graft 3D neural microtissue product – manufactured at large scale – as a therapeutically viable option to treat Parkinson’s…
  • 2024 International Congress

    Opicapone Reduces Homocysteine Levels in Patients with Parkinson’s Disease Treated with Levodopa Gel Infusion

    M. Minar, I. Straka, Z. Kosutzka, Z. Andre (Bratislava, Slovakia)

    Objective: Our study aims to assess the effect of an add-on treatment with catechol-O-methyl transferase (COMT) inhibitor, opicapone, on the plasmatic levels of homocysteine (HCY)…
  • 2024 International Congress

    Writing rehabilitation in parkinson’s disease (pd) through a virtual workshop

    F. Echeverria, P. Sanchez Diaz, S. Revellini, G. Costa, G. Ziegler, S. Rodriguez Quiroga, T. Arakaki, N. Garretto (Buenos Aires, Argentina)

    Objective: Evaluate the effect of intensive writing training through a virtual workshop once a week and the potential influence in the quality of life in…
  • 2024 International Congress

    Chronic Sleep Fragmentation Accelerates the Onset of Prodromal Symptoms and Pathology in Parkinson’s Disease Model Mice

    M. Miyazaki, H. Yagihara, H. Fujita, H. Yamakado, K. Wada, E. Minakawa (Kodaira, Japan)

    Objective: To investigate whether chronic sleep fragmentation accelerates the onset of prodromal symptoms and pathology of Parkinson’s disease (PD) in mice. Background: The prodromal phase…
  • « Previous Page
  • 1
  • …
  • 176
  • 177
  • 178
  • 179
  • 180
  • 181
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley